Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Bicycle Therapeutics PLC Sponsored ADR stock logo
BCYC
Bicycle Therapeutics
$7.17
-3.5%
$8.05
$6.10
$28.67
$514.56M1.41396,212 shs220,633 shs
Metsera Inc. stock logo
MTSR
Metsera
$28.39
-3.6%
$27.65
$12.30
$37.99
$3.09BN/A1.05 million shs483,938 shs
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
$35.59
-6.8%
$33.40
$27.12
$60.90
$2.29B2.41967,350 shs1.06 million shs
Vericel Corporation stock logo
VCEL
Vericel
$39.41
-5.6%
$41.70
$37.39
$63.00
$2.10B1.32417,952 shs486,140 shs
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Bicycle Therapeutics PLC Sponsored ADR stock logo
BCYC
Bicycle Therapeutics
-3.43%+3.17%-16.14%+12.38%-64.52%
Metsera Inc. stock logo
MTSR
Metsera
-3.60%-0.21%+3.27%+99.79%+2,838,999,900.00%
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
-6.61%-3.26%+12.73%+1.17%-26.57%
Vericel Corporation stock logo
VCEL
Vericel
-5.68%-7.38%-8.98%+2.10%-15.57%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Bicycle Therapeutics PLC Sponsored ADR stock logo
BCYC
Bicycle Therapeutics
3.6527 of 5 stars
4.44.00.00.02.41.70.6
Metsera Inc. stock logo
MTSR
Metsera
N/AN/AN/AN/AN/AN/AN/AN/A
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
4.5244 of 5 stars
4.42.00.04.43.40.80.6
Vericel Corporation stock logo
VCEL
Vericel
2.945 of 5 stars
3.51.00.00.03.30.81.9
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Bicycle Therapeutics PLC Sponsored ADR stock logo
BCYC
Bicycle Therapeutics
2.70
Moderate Buy$25.00248.68% Upside
Metsera Inc. stock logo
MTSR
Metsera
3.00
Buy$55.0093.73% Upside
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
2.70
Moderate Buy$50.4041.61% Upside
Vericel Corporation stock logo
VCEL
Vericel
3.00
Buy$61.1455.15% Upside

Current Analyst Ratings Breakdown

Latest BCYC, TWST, MTSR, and VCEL Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/20/2025
Metsera Inc. stock logo
MTSR
Metsera
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$65.00
6/16/2025
Vericel Corporation stock logo
VCEL
Vericel
Stephens
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$67.00
6/10/2025
Metsera Inc. stock logo
MTSR
Metsera
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$56.00 ➝ $62.00
5/22/2025
Vericel Corporation stock logo
VCEL
Vericel
Stephens
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$67.00 ➝ $67.00
5/6/2025
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$55.00 ➝ $48.00
5/6/2025
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$50.00 ➝ $50.00
5/6/2025
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$54.00 ➝ $44.00
5/6/2025
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetUnderweight ➝ Underweight$40.00 ➝ $33.00
5/5/2025
Bicycle Therapeutics PLC Sponsored ADR stock logo
BCYC
Bicycle Therapeutics
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetEqual Weight ➝ Equal Weight$15.00 ➝ $17.00
5/2/2025
Bicycle Therapeutics PLC Sponsored ADR stock logo
BCYC
Bicycle Therapeutics
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$35.00 ➝ $32.00
5/2/2025
Bicycle Therapeutics PLC Sponsored ADR stock logo
BCYC
Bicycle Therapeutics
B. Riley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$17.00 ➝ $14.00
(Data available from 7/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Bicycle Therapeutics PLC Sponsored ADR stock logo
BCYC
Bicycle Therapeutics
$35.28M14.07N/AN/A$11.48 per share0.62
Metsera Inc. stock logo
MTSR
Metsera
N/AN/AN/AN/A($2.46) per shareN/A
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
$312.97M6.81N/AN/A$8.07 per share4.41
Vericel Corporation stock logo
VCEL
Vericel
$237.22M8.36$0.30 per share133.57$5.92 per share6.66
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Bicycle Therapeutics PLC Sponsored ADR stock logo
BCYC
Bicycle Therapeutics
-$169.03M-$3.14N/AN/AN/A-790.07%-25.54%-21.23%8/5/2025 (Estimated)
Metsera Inc. stock logo
MTSR
Metsera
-$209.13MN/A0.00N/AN/AN/AN/AN/A
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
-$208.73M-$3.25N/AN/AN/A-54.98%-33.48%-25.34%8/1/2025 (Estimated)
Vericel Corporation stock logo
VCEL
Vericel
$10.36M$0.031,314.1089.57N/A1.25%1.09%0.73%7/30/2025 (Estimated)

Latest BCYC, TWST, MTSR, and VCEL Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/1/2025Q3 2025
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
-$0.54N/AN/AN/A$95.52 millionN/A
5/12/2025Q1 2025
Metsera Inc. stock logo
MTSR
Metsera
N/A-$1.03N/A-$1.03N/AN/A
5/8/2025Q1 2025
Vericel Corporation stock logo
VCEL
Vericel
-$0.09-$0.23-$0.14-$0.23$53.86 million$52.60 million
5/5/2025Q2 2025
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
-$0.56-$0.66-$0.10-$0.66$92.00 million$92.79 million
5/1/2025Q1 2025
Bicycle Therapeutics PLC Sponsored ADR stock logo
BCYC
Bicycle Therapeutics
-$0.86-$0.88-$0.02-$0.88$8.67 million$9.98 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Bicycle Therapeutics PLC Sponsored ADR stock logo
BCYC
Bicycle Therapeutics
N/AN/AN/AN/AN/A
Metsera Inc. stock logo
MTSR
Metsera
N/AN/AN/AN/AN/A
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
N/AN/AN/AN/AN/A
Vericel Corporation stock logo
VCEL
Vericel
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Bicycle Therapeutics PLC Sponsored ADR stock logo
BCYC
Bicycle Therapeutics
N/A
14.86
14.86
Metsera Inc. stock logo
MTSR
Metsera
N/A
6.55
6.55
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
0.03
4.51
4.24
Vericel Corporation stock logo
VCEL
Vericel
N/A
5.01
4.58

Institutional Ownership

CompanyInstitutional Ownership
Bicycle Therapeutics PLC Sponsored ADR stock logo
BCYC
Bicycle Therapeutics
86.15%
Metsera Inc. stock logo
MTSR
Metsera
N/A
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
N/A
Vericel Corporation stock logo
VCEL
Vericel
N/A

Insider Ownership

CompanyInsider Ownership
Bicycle Therapeutics PLC Sponsored ADR stock logo
BCYC
Bicycle Therapeutics
8.50%
Metsera Inc. stock logo
MTSR
Metsera
N/A
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
3.01%
Vericel Corporation stock logo
VCEL
Vericel
7.20%
CompanyEmployeesShares OutstandingFree FloatOptionable
Bicycle Therapeutics PLC Sponsored ADR stock logo
BCYC
Bicycle Therapeutics
24069.25 million63.37 millionOptionable
Metsera Inc. stock logo
MTSR
Metsera
81105.06 millionN/AN/A
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
99059.92 million58.11 millionOptionable
Vericel Corporation stock logo
VCEL
Vericel
30050.34 million46.72 millionOptionable

Recent News About These Companies

Vericel Corporation: Moving From Sell To Neutral

New MarketBeat Followers Over Time

Media Sentiment Over Time

Bicycle Therapeutics stock logo

Bicycle Therapeutics NASDAQ:BCYC

$7.17 -0.26 (-3.50%)
Closing price 07/7/2025 04:00 PM Eastern
Extended Trading
$7.16 0.00 (-0.07%)
As of 07/7/2025 05:53 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial. The company also developing BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease; and BT7401, a multivalent bicycle CD137 agonist which is in phase IIa to treat advanced solid tumors. In addition, it develops Novel anti-infective, which is in preclinical trial targeting anti-infectives disease; CNS targets, which is in preclinical trial targeting CNS disease; and Novel neuromuscular targets, which is in preclinical trial targeting neuromuscular disease. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas. It has collaboration and license agreement with Bayer Consumer Care AG; Novartis Pharma AG; Cancer Research UK; Cancer Research Technology Ltd; and Oxurion NV. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.

Metsera stock logo

Metsera NASDAQ:MTSR

$28.39 -1.06 (-3.60%)
As of 07/7/2025 04:00 PM Eastern

Metsera, Inc. is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o. The company was founded by Clive A. Meanwell in 2022 and is headquartered in New York.

Twist Bioscience stock logo

Twist Bioscience NASDAQ:TWST

$35.59 -2.58 (-6.76%)
Closing price 07/7/2025 04:00 PM Eastern
Extended Trading
$36.04 +0.45 (+1.26%)
As of 07/7/2025 07:26 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels, primarily used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, the company provides synthetic SARS-CoV-2 RNA reference sequences as positive controls for the development of both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries used for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company was incorporated in 2013 and is headquartered in South San Francisco, California.

Vericel stock logo

Vericel NASDAQ:VCEL

$39.41 -2.33 (-5.58%)
Closing price 07/7/2025 04:00 PM Eastern
Extended Trading
$39.40 0.00 (-0.01%)
As of 07/7/2025 06:06 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.